BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 10866371)

  • 1. Novel inhibitors of HIV protease: design, synthesis and biological evaluation of picomolar inhibitors containing cyclic P1/P2 scaffolds.
    Spaltenstein A; Almond MR; Bock WJ; Cleary DG; Furfine ES; Hazen RJ; Kazmierski WM; Salituro FG; Tung RD; Wright LL
    Bioorg Med Chem Lett; 2000 Jun; 10(11):1159-62. PubMed ID: 10866371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands.
    Ali A; Reddy GS; Cao H; Anjum SG; Nalam MN; Schiffer CA; Rana TM
    J Med Chem; 2006 Dec; 49(25):7342-56. PubMed ID: 17149864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains.
    Miller JF; Furfine ES; Hanlon MH; Hazen RJ; Ray JA; Robinson L; Samano V; Spaltenstein A
    Bioorg Med Chem Lett; 2004 Feb; 14(4):959-63. PubMed ID: 15013001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles.
    Miller JF; Brieger M; Furfine ES; Hazen RJ; Kaldor I; Reynolds D; Sherrill RG; Spaltenstein A
    Bioorg Med Chem Lett; 2005 Aug; 15(15):3496-500. PubMed ID: 15990305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.
    Ghosh AK; Swanson LM; Cho H; Leshchenko S; Hussain KA; Kay S; Walters DE; Koh Y; Mitsuya H
    J Med Chem; 2005 May; 48(10):3576-85. PubMed ID: 15887965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel, picomolar inhibitor of human immunodeficiency virus type 1 protease.
    Sham HL; Zhao C; Stewart KD; Betebenner DA; Lin S; Park CH; Kong XP; Rosenbrook W; Herrin T; Madigan D; Vasavanonda S; Lyons N; Molla A; Saldivar A; Marsh KC; McDonald E; Wideburg NE; Denissen JF; Robins T; Kempf DJ; Plattner JJ; Norbeck DW
    J Med Chem; 1996 Jan; 39(2):392-7. PubMed ID: 8558507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent inhibitors of the HIV-1 protease incorporating cyclic urea P1-P2 scaffold.
    Kazmierski WM; Furfine E; Gray-Nunez Y; Spaltenstein A; Wright L
    Bioorg Med Chem Lett; 2004 Nov; 14(22):5685-7. PubMed ID: 15482948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclic HIV protease inhibitors: design and synthesis of orally bioavailable, pyrazole P2/P2' cyclic ureas with improved potency.
    Han Q; Chang CH; Li R; Ru Y; Jadhav PK; Lam PY
    J Med Chem; 1998 Jun; 41(12):2019-28. PubMed ID: 9622543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
    Jadhav PK; Ala P; Woerner FJ; Chang CH; Garber SS; Anton ED; Bacheler LT
    J Med Chem; 1997 Jan; 40(2):181-91. PubMed ID: 9003516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lysine sulfonamides as novel HIV-protease inhibitors: Nepsilon-acyl aromatic alpha-amino acids.
    Stranix BR; Lavallée JF; Sévigny G; Yelle J; Perron V; LeBerre N; Herbart D; Wu JJ
    Bioorg Med Chem Lett; 2006 Jul; 16(13):3459-62. PubMed ID: 16644213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, asymmetric synthesis, and evaluation of pseudosymmetric sulfoximine inhibitors against HIV-1 protease.
    Lu D; Sham YY; Vince R
    Bioorg Med Chem; 2010 Mar; 18(5):2037-48. PubMed ID: 20138769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of novel HIV-1 protease inhibitors incorporating oxyindoles as the P2'-ligands.
    Ghosh AK; Schiltz G; Perali RS; Leshchenko S; Kay S; Walters DE; Koh Y; Maeda K; Mitsuya H
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1869-73. PubMed ID: 16480871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved P1/P1' substituents for cyclic urea based HIV-1 protease inhibitors: synthesis, structure-activity relationship, and X-ray crystal structure analysis.
    Nugiel DA; Jacobs K; Cornelius L; Chang CH; Jadhav PK; Holler ER; Klabe RM; Bacheler LT; Cordova B; Garber S; Reid C; Logue KA; Gorey-Feret LJ; Lam GN; Erickson-Viitanen S; Seitz SP
    J Med Chem; 1997 May; 40(10):1465-74. PubMed ID: 9154969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors possessing augmented P2' side chains.
    Smith AB; Charnley AK; Harada H; Beiger JJ; Cantin LD; Kenesky CS; Hirschmann R; Munshi S; Olsen DB; Stahlhut MW; Schleif WA; Kuo LC
    Bioorg Med Chem Lett; 2006 Feb; 16(4):859-63. PubMed ID: 16298527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclic HIV-1 protease inhibitors derived from mannitol: synthesis, inhibitory potencies, and computational predictions of binding affinities.
    Hultén J; Bonham NM; Nillroth U; Hansson T; Zuccarello G; Bouzide A; Aqvist J; Classon B; Danielson UH; Karlén A; Kvarnström I; Samuelsson B; Hallberg A
    J Med Chem; 1997 Mar; 40(6):885-97. PubMed ID: 9083477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of novel P2 substituents in diol-based HIV protease inhibitors.
    Adrian Meredith J; Wallberg H; Vrang L; Oscarson S; Parkes K; Hallberg A; Samuelsson B
    Eur J Med Chem; 2010 Jan; 45(1):160-70. PubMed ID: 19926360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and evaluation of A-seco type triterpenoids for anti-HIV-1protease activity.
    Wei Y; Ma CM; Hattori M
    Eur J Med Chem; 2009 Oct; 44(10):4112-20. PubMed ID: 19493591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonsymmetrically substituted cyclic urea HIV protease inhibitors.
    Wilkerson WW; Dax S; Cheatham WW
    J Med Chem; 1997 Dec; 40(25):4079-88. PubMed ID: 9406598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and antiviral property of allophenylnorstatine-based HIV protease inhibitors incorporating D-cysteine derivatives as P2/P3 moieties.
    Ami E; Nakahara K; Sato A; Nguyen JT; Hidaka K; Hamada Y; Nakatani S; Kimura T; Hayashi Y; Kiso Y
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4213-7. PubMed ID: 17537628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and synthesis of novel conformationally restricted HIV protease inhibitors.
    Salituro FG; Baker CT; Court JJ; Deininger DD; Kim EE; Li B; Novak PM; Rao BG; Pazhanisamy S; Porter MD; Schairer WC; Tung RD
    Bioorg Med Chem Lett; 1998 Dec; 8(24):3637-42. PubMed ID: 9934485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.